Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 340 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: tenofovir/emtricitabine (TDF/FTC) Clear all
Completed Phase 4 Interventional Results available

Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients

NCT00762892
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir and truvada, Atazanavir, Norvir and Truvada
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers

NCT03202511
View directory record Official record
Conditions
Pre-Exposure Prophylaxis
Interventions
Probenecid Oral Tablet, Tenofovir disoproxil fumarate/Emtricitabine
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers

NCT01276600
View directory record Official record
Conditions
HIV
Interventions
Emtricitabine/tenofovir
Drug
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years to 44 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

NCT02269917
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1
Interventions
D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
38
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 4 Interventional Results available

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

NCT01285050
View directory record Official record
Conditions
HIV Infection, Hepatitis C
Interventions
Antiretroviral therapy (ART), raltegravir, Emtricitabine and tenofovir disoproxil fumarate
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

LAAM-HAART PET Imaging

NCT01935830
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[11c] LAAM, Ritonavir, Efavirenz
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 1 Interventional

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

NCT04006704
View directory record Official record
Conditions
HIV-1
Interventions
D/C/F/TAF FDC placebo
Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
6 Years to 11 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 14, 2026, 10:02 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

NCT04652700
View directory record Official record
Conditions
HIV Preexposure Prophylaxis
Interventions
ISL, FTC/TDF, FTC/TAF, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

NCT00507507
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Tenofovir DF, FTC, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 69 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States

NCT00936715
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
FTC/TDF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 3 Interventional

Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects

NCT00043966
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Tenofovir DF, Emtricitabine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
29
States / cities
Phoenix, Arizona • Beverly Hills, California • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2006 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 4 Interventional Results available

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)

NCT01102972
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Reyataz + Norvir + Truvada, Reyataz + Epzicom
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
44
States / cities
Hobson City, Alabama • Phoenix, Arizona • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 14, 2026, 10:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safer Conception Intervention for HIV-1 Serodiscordant Couples

NCT03030768
View directory record Official record
Conditions
HIV Seropositivity, Pregnancy, High-Risk
Interventions
PrEP, Counseling on timed condomless sex, ART and PrEP adherence
Drug · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 49 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)

NCT03499483
View directory record Official record
Conditions
HIV Prevention
Interventions
bictegravir
Drug
Lead sponsor
Fenway Community Health
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"

NCT05528653
View directory record Official record
Conditions
HIV Prevention
Interventions
Descovy
Drug
Lead sponsor
Vivent Health
Other
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Denver, Colorado • St Louis, Missouri • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 4 Interventional Results available

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain

NCT04442737
View directory record Official record
Conditions
HIV-1
Interventions
D/C/F/TAF FDC, TAF/FTC FDC, INI Based Regimen
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
34
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

NCT00869557
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Stribild, Atripla
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
30
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)

NCT00924898
View directory record Official record
Conditions
Acute HIV Infection, HIV Infections
Interventions
efavirenz, emtricitabine, and tenofovir
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor

NCT04870671
View directory record Official record
Conditions
HIV/AIDS, Adherence, Medication, Drug Use
Interventions
Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Early Phase 1 Interventional

Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV

NCT04820933
View directory record Official record
Conditions
HIV I Infection, Cardiovascular Risk Factor, Lipid Metabolism Disorders
Interventions
Doravirine 100 Mg
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 4 Interventional Results available

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

NCT00414635
View directory record Official record
Conditions
HIV Infections
Interventions
Intermitent Dosing
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

NCT01687218
View directory record Official record
Conditions
HIV
Interventions
Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet), Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel), Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older · Male only
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

PrEP at a Syringe Services Program

NCT04782180
View directory record Official record
Conditions
Hiv, Substance Use Disorders
Interventions
Descovy 200Mg 25Mg Tablet, PrEP
Drug · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 14, 2026, 10:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sustainable Healthcenter Implementation PrEP Pilot Study

NCT02074891
View directory record Official record
Conditions
HIV Chemoprophylaxis, HIV Preexposure Prophylaxis
Interventions
coformulated TDF/FTC
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
1,420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 14, 2026, 10:02 PM EDT